Publication:
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Simple item page
dc.contributor.authorCakirca, MUSTAFA
dc.contributor.authorSoysal, Pinar
dc.contributor.authorZorlu, MEHMET
dc.contributor.authorKiskac, MUHARREM
dc.contributor.authorKanat, Mustafa
dc.contributor.authorCIKRIKCIOGLU, Mehmet Ali
dc.contributor.authorKaratoprak, CUMALİ
dc.contributor.authorHURSITOGLU, Mehmet
dc.contributor.authorCamli, AHMET ADİL
dc.contributor.authorERKOC, Reha
dc.contributor.authorABDUL-GHANI, Muhammad
dc.contributor.institutionauthorÇAKIRCA, MUSTAFA
dc.contributor.institutionauthorKARATOPRAK, CUMALİ
dc.contributor.institutionauthorZORLU, MEHMET
dc.contributor.institutionauthorKISKAÇ, MUHARREM
dc.contributor.institutionauthorSOYSAL, PINAR
dc.contributor.institutionauthorÇAMLI, AHMET ADİL
dc.date.accessioned2019-10-05T21:57:58Z
dc.date.available2019-10-05T21:57:58Z
dc.date.issued2014-01-01
dc.description.abstractAims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.en
dc.identifier
dc.identifier.citationCakirca M., Karatoprak C., Zorlu M., Kiskac M., Kanat M., CIKRIKCIOGLU M. A. , Soysal P., HURSITOGLU M., Camli A. A. , ERKOC R., et al., -Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients-, DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.8, ss.239-243, 2014
dc.identifier.pubmed24627624
dc.identifier.urihttps://hdl.handle.net/20.500.12645/8567
dc.identifier.wosWOS:000331555100001
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjecttype 2 diabetes
dc.titleEffect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
dc.typeArticle
dspace.entity.typePublication
local.article.journalnameSWISS MEDICAL WEEKLY
local.avesis.idd5c23d07-1035-470f-b0e4-8a04f13e48a1
local.avesis.response8443
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
relation.isAuthorOfPublicationdbdeb67c-4919-4301-ba66-74403068133b
relation.isAuthorOfPublicationb04cfc56-9dea-4145-a140-c66dc7ace166
relation.isAuthorOfPublication72084e17-e46e-438f-925e-0a24ad5f9850
relation.isAuthorOfPublication777d95d8-6fb6-4952-80c1-727755625e7e
relation.isAuthorOfPublication0e36986e-d71d-4579-a395-877af097ade5
relation.isAuthorOfPublicationca17c745-9915-47c0-8887-702bfb63d86e
relation.isAuthorOfPublication.latestForDiscovery0e36986e-d71d-4579-a395-877af097ade5
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
108- Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients..pdf
Size:
214.89 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler
Tıp Fakültesi